PURPOSE: Evaluating the role of cystone, a polyherbal preparation, in protecting cancer patients againstcisplatin-induced nephrotoxicity, and its impact on the cytotoxic activity of cisplatin. METHODS: A prospective open-label randomized controlled trial conducted on 49 cancer patients who received six cycles of 70 mg/m(2) cisplatin-based regimens. The study comprised two groups, a control group (A) in which 28 patients received cisplatin without cystone supplement, and an experimental group (B) in which 21 patients received cisplatin with cystone supplement. Renal function parameters including serum creatinine, creatinine clearance, blood urea, and serum cystatin C were compared between both groups throughout chemotherapy cycles. Patient response to treatment was evaluated in both groups after 3rd and 6th cycles. RESULTS: At the end of the study, mean levels of serum creatinine, blood urea, and serum cystatin C were significantly lower, whereas creatinine clearance was significantly higher in group (B) compared with group (A). In group (B), there was no significant difference between mean levels of renal markers at baseline and after completion of treatment; while significant changes were observed in group (A). Grading of acute kidney injury according to Common Terminology Criteria for Adverse Events revealed significantly better renal status among patients in group (B) "grades 0 and 1 in 76 and 24 % of the patients, respectively" compared with group (A) "grades 0, 1, and 2 in 36, 32, and 32 % of the patients, respectively". Based on Response Evaluation Criteria in Solid Tumors, there was no significant difference between both groups. CONCLUSIONS:Cystone can protect cancer patients from cisplatin nephrotoxicity without interfering with its antitumor activity.
RCT Entities:
PURPOSE: Evaluating the role of cystone, a polyherbal preparation, in protecting cancerpatients against cisplatin-induced nephrotoxicity, and its impact on the cytotoxic activity of cisplatin. METHODS: A prospective open-label randomized controlled trial conducted on 49 cancerpatients who received six cycles of 70 mg/m(2) cisplatin-based regimens. The study comprised two groups, a control group (A) in which 28 patients received cisplatin without cystone supplement, and an experimental group (B) in which 21 patients received cisplatin with cystone supplement. Renal function parameters including serum creatinine, creatinine clearance, blood urea, and serum cystatin C were compared between both groups throughout chemotherapy cycles. Patient response to treatment was evaluated in both groups after 3rd and 6th cycles. RESULTS: At the end of the study, mean levels of serum creatinine, blood urea, and serum cystatin C were significantly lower, whereas creatinine clearance was significantly higher in group (B) compared with group (A). In group (B), there was no significant difference between mean levels of renal markers at baseline and after completion of treatment; while significant changes were observed in group (A). Grading of acute kidney injury according to Common Terminology Criteria for Adverse Events revealed significantly better renal status among patients in group (B) "grades 0 and 1 in 76 and 24 % of the patients, respectively" compared with group (A) "grades 0, 1, and 2 in 36, 32, and 32 % of the patients, respectively". Based on Response Evaluation Criteria in Solid Tumors, there was no significant difference between both groups. CONCLUSIONS: Cystone can protect cancerpatients from cisplatinnephrotoxicity without interfering with its antitumor activity.
Authors: Neife Aparecida Guinaim dos Santos; Maria Augusta Carvalho Rodrigues; Nadia Maria Martins; Antonio Cardozo dos Santos Journal: Arch Toxicol Date: 2012-03-01 Impact factor: 5.153
Authors: Marika H Grönroos; Timo Jahnukainen; Kerttu Irjala; Risto Härkönen; Saija Hurme; Merja Möttönen; Toivo T Salmi Journal: Pediatr Nephrol Date: 2008-01-23 Impact factor: 3.714
Authors: F E de Jongh; R N van Veen; S J Veltman; R de Wit; M E L van der Burg; M J van den Bent; A S Th Planting; W J Graveland; G Stoter; J Verweij Journal: Br J Cancer Date: 2003-04-22 Impact factor: 7.640
Authors: Marcello Tiseo; Olga Martelli; Andrea Mancuso; Maria Pia Sormani; Paolo Bruzzi; Roberto Di Salvia; Filippo De Marinis; Andrea Ardizzoni Journal: Tumori Date: 2007 Mar-Apr
Authors: Alfredo G Casanova; María Teresa Hernández-Sánchez; Francisco J López-Hernández; Carlos Martínez-Salgado; Marta Prieto; Laura Vicente-Vicente; Ana Isabel Morales Journal: Eur J Clin Pharmacol Date: 2019-11-01 Impact factor: 2.953